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a b s t r a c t
Ethnopharmacological relevance: The roots of Salvia milthorriza Bunge (Lamiaceae) known as “Danshen”,
are used in Traditional Chinese Medicine as a remedy for activating blood and eliminating stasis. TIIA,
a diterpenoid of Salvia milthorriza, is one of active components in Danshen that exhibits a signiﬁcant
improvement of the blood ﬂow in the coronary circulatory system and a reduction of myocardial
infarction. However, its effect on platelet and underlying mechanism remains largely unknown. On this
basis, this compound could be a promising agent to improve blood viscosity and microcirculation and to
prevent CVD.
Materials and methods: In order to investigate the effects of TIIA on platelet functionality and its
interaction with various platelet activation pathways, rat PRP were incubated with TIIA for 1 min at 37 1C
prior the addition of the stimuli (ADP or collagen). Aggregation was monitored in a light transmission
aggregometer measuring changes in turbidity with continuous observation up to 10 min after the
addition of the stimuli. MAPK signaling pathway and tubulin acetylation were analyzed by a Western blot
technique. The effect of the TIIA was also studied in vivo on bleeding time in mice.
Results: TIIA selectively inhibited rat platelet aggregation induced by reversible ADP stimuli (3 μM) in
a concentration-dependent manner (0.5–50 μM). Nevertheless, TIIA was less active against the
irreversible stimuli induced by ADP (10 μM) and collagen (10 μg/mL). Moreover, experiments performed
on platelet lysates collected at different time-point after the addition of the stimuli shown that TIIA
modulated tubulin acetylation and inhibited Erk-2 phosphorylation. Concomitantly, TIIA administrated i.p. at
10 mg/kg signiﬁcantly ampliﬁed the mice bleeding time with an increase of 58% compared to its control
(2.067
0.29 min vs 1.3070.07). ASA was used as reference drug for in vitro and in vivo experiments.
Conclusions: This study clariﬁes the intracellular signaling pathway involved in antiplatelet action of TIIA and
also gives preliminary evidences for its anticoagulant activity. On this basis, this compound could be a
promising agent to improve blood viscosity and microcirculation and to prevent CVD.
& 2014 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
CVD and its main underlying cause, atherothrombosis, are the
major causes of morbidity and mortality worldwide (Yusuf et al.,
2001). Platelet aggregation is a crucial step in normal hemostasis
and in the development and progression of atherothrombosis
(Kalra et al., 2013). For these reasons, pharmacological therapies
with agents that inhibit platelet reactivity have proven to be
effective in the treatment and/or in the prevention of CVD
(Binazon et al., 2013; Silva et al., 2013). Moreover, advances in
the knowledge of both platelet biology and biological functions of
natural products can provide new avenues to develop pharmaco-
logical strategies aimed to promote cardiovascular health (Bonito
et al., 2011; Vilahur and Badimon, 2013; Maione et al., 2013).
Danshen is a crude herbal drug isolated from dried root of Salvia
miltiorrhiza Bunge (Lamiaceae). This plant is widely used in Asia,
United States of America and European countries for the treatment
of cardiovascular and cerebrovascular diseases (Wang et al., 2007).
The beneﬁcial actions are attributable to improve microcirculatory,
vasodilatory, anti-coagulant, anti-thrombotic, anti-inﬂammatory, free
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radical scavenging, and mitochondria-protective effects. Although
Danshen is ofﬁcially listed in the Chinese Pharmacopoeia, the phar-
macology of its active constituents is not yet fully described (Cheng,
2006; Zhou et al., 2005; Han et al., 2008).
TIIA is one of the most pharmacological lipophilic active
components isolated from Danshen. Many experimental and
clinical investigations have reported that this diterpenoid can
prevent or slow the progression of a wide spectrum of diseases,
including CVD, cancer, neonatal hypoxic ischemic encephalopathy
as well as neurodegenerative diseases (Takahashi et al., 2002; Wu
et al., 1993). Moreover, an increasing number of evidences show
that TIIA is involved in pathological organ injury induced by
ischemia and reperfusion (Han et al., 2008), in immune vasculitis
(Li et al., 2009) and in inhibition of platelet aggregation and
thrombus formation (Liu et al., 2011; Li et al., 1984; Ji et al.,
2008). However, its effect on platelet and underlying mechanism
remain largely unknown and considerable efforts are still being
devoted to clarify these aspects.
To provide further insights, in this study we tested the
hypothesis that TIIA inhibited the platelet aggregation induced
by collagen and ADP via the modulation of tubulin acetylation and
inhibition of Erk-2 phosphorilation. The effect of the diterpenoid
was also studied in vivo on bleeding time in mice.
2. Materials and methods
2.1. Animals
Male Wistar rats and CD1 mice (250–300 g and 25–30 g
respectively; Harlan Nossan, Correzzana, Milan, Italy) were used
for all the experiments. Animals were kept under standard
conditions, with food and water ad libitum and maintained in
a 12 h/12 h light/dark cycle at 2271 1C. All the in vivo proce-
dures were in accordance with the Italian legislative decree (D.
L.) no. 116 of January 27, 1992 and associates European Com-
munity guidelines (EEC Directive of 1986; 86/609/EEC). All
efforts were made to minimize animal suffering and to reduce
their number.
2.2. Reagents
Tanshinone IIA (Z 97%, HPLC), adenosine diphosphate (ADP)
and acetylsalicylic acid (ASA) were obtained from Sigma-Aldrich
Co. (Milan, Italy). For Western blot, the primary antibodies mouse
monoclonal anti-phospho Erk2 and anti-Erk2 with related horse-
radish peroxidase conjugated secondary antibodies were obtained
from Santa Cruz Biotechnology (Milan, Italy). The primary anti-
bodies mouse monoclonal anti-acetylated tubulin and anti-tubulin
were obtained from Sigma-Aldrich Co. (Milan, Italy). Unless
otherwise stated, all the other reagents were from Carlo Erba
Reagents (Milan, Italy).
2.3. In vitro platelet aggregation assay
In vitro platelet aggregation was measured according to the
turbidimetric method, using two-channel aggregometer
(Chrono-Log, Corporation, Mod. 490, USA). Blood anticoagulated
with 3.2% sodium citrate (1:9 citrate/blood, v/v) was withdrawn
from male Wistar rats (anesthetized by enﬂurane) by cardiac
puncture. Platelet-rich plasma (PRP) and platelet-poor plasma
(PPP) were prepared as previously described (Pearce et al., 2004;
Cicala et al., 2007). Brieﬂy, PRP was obtained by centrifugation at
800 rpm for 15 min at 25 1C. PPP was prepared from the pre-
cipitated fraction of PRP by centrifugation at 2000 rpm for 20 min
at 25 1C. PRP was adjusted to 3108 platelets/mL. Next, 250 μL of
PRP were incubated at 37 1C for 1 min in the cuvette with 20 μL
of TIIA solution at ﬁnal concentration of 0.5, 5 and 50 μM. ASA
(50 μM) and TIIA-vehicle (0.3% methanol in distilled water) or
ASA-vehicle (3.3% DMSO in distilled water) were used as control
and reference drug, respectively. After incubation, platelet aggre-
gation was induced by the addition of 20 μL ADP (3–10 μM) or
collagen (10 μg/mL). The maximum platelet aggregation rate was
recorded within 10 min with continuous stirring at 37 1C. The
light transmittance was calibrated with PPP. The percentage (%)
of inhibition of platelet aggregation was calculated by the
following formula: [(XY)/X] 100%. X was the maximum
aggregation rate of vehicle-treated PRP; Y was the maximum
aggregation rate of sample-treated PRP and was expressed in
terms of amplitude (% of aggregation at a given time interval from
reagent addition) or AUC (% of total response duration from
reagent addition).
2.4. Western blot analysis
Platelets (3108 platelets/mL) were stimulated with ADP
(3 μM) in the presence of TIIA (50 mM) or its vehicle and imme-
diately stopped adding 250 μL of formaldehyde buffer (4% for-
maldehyde in saline) at different times (1,3 and 5 min). We have
selected the indicated time point in order to evaluate platelets
intracellular signaling during the ﬁrst ascending wave (1 min), the
plateau (3 min) and the descending wave (5 min) of aggregation
curve. Successively, platelets suspension was collected, washed
with PBS and centrifuged. The platelet pellet was then lysed in the
following lysis buffer: Tris–HCl (pH:7.5, 50 mM), NaCl (150 mM),
glycerophosphate (20 mM), EDTA (2 mM), PMSF (1 mM), sodium
ortovanadate (1 mM), leupeptin (5 mg/ml), aprotinin (5 mg/mL),
pepstatin (5 mg/ml). Protein concentration was determined by
the Bio-Rad protein assay kit (Bio-Rad, Italy). Protein samples
(50 mg) were subjected to electrophoresis on an SDS 12% poly-
acrylamide gel and transferred onto a nitrocellulose transfer
membrane, using standard procedure as previously described
(Pederzoli-Ribeil et al., 2010; Maione et al., 2011; Iqbal et al.,
2011). The membranes were saturated by incubation with non-fat
dry milk (5% wt/v) in PBS supplemented with 0.1% (v/v) Tween 20
(PBS-T) for 2 h at room temperature and then incubated with a
primary antibody (mouse monoclonal anti-phospho Erk2; dilution
1:500, anti-Erk2, anti-acetylated tubulin or anti-tubulin; dilution
1:2000), overnight at 4 1C. Successively, membranes were washed
3 times with PBS-T and then incubated with the secondary
antibody conjugated with horseradish peroxidase, anti-mouse
IgG-HRP (dilution 1:2000), for 2 h at room temperature. Protein
bands were detected using the enhanced chemiluminescence
(ECL) detection kit and Image Quant 400 GE Healthcare software
(GE Healthcare, Italy). Protein bands for p-Erk and acetylated-
tubulin were quantiﬁed using GS 800 imaging densitometer soft-
ware (Biorad, Italy) and normalized with respective Erk-2 and
tubulin.
2.5. In vivo assessment of tail bleeding time.
The bleeding time was assayed according to the described
method with slight changes (Bowie and Owen, 1974). Mice were
anaesthetized intraperitoneally (i.p.) with a mixture of ketamine
(75 mg/kg) and xylazine (10 mg/kg) and the tail was pre-warmed
for 3 min in a 0.9% saline solution at 37 1C 1 h after the i.p.
injection of TIIA (10 mg/kg), ASA (10 mg/kg) and their vehicles
(8% methanol in saline and 1% CMC in saline respectively for TIIA
and ASA). The bleeding was induced by precise transaction of the
mouse tail at 5 mm from the tip. The distal portion of the tail
(3 cm) was immersed vertically into the 0.9% saline solution at
37 1C. Blood ﬂowing from the incision was carefully monitored and
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the time to cessation of bleeding was recorded as the bleeding
time. Bleeding cessation was considered to be the time when the
ﬂow of blood stops.
2.6. Statistical analysis
All assays were repeated at least in triplicate and the results
were expressed as mean7standard error of mean (SEM). Results
were analyzed with one way analysis of variance (ANOVA),
followed by Bonferroni's test for multiple comparisons, or by
unpaired two tailed Student's t-test when appropriate. In some
cases, One Sample t-test was used to evaluate signiﬁcance against
the hypothetical zero value. The analysis was performed using
GraphPad Prism Software version 4.0. P values less than 0.05 were
considered signiﬁcant.
3. Results
3.1. Effect of TIIA on rat platelet aggregation
Fig. 1 shows typical records of concentration-dependent effect
of TIIA (0.5, 5 and 50 mM) and the effect of ASA (50mM) on ADP-
induced rat platelet aggregation.
Fig. 2 shows a concentration-dependent inhibition of reversible
platelet aggregation expressed as % of inhibition of AUC (Fig.1A) or
amplitude (Fig.1B) induced by TIIA (0.5, 5 and 50 mM) and ASA
(50 mM) added 1 min before the addition of ADP (3 mM). TIIA and
ASA at a concentration of 50 mM displayed the maximum inhibi-
tory activity in terms of inhibition of AUC (63.3711.3%; Po0.001
and 86.073.78%; Po0.001) and amplitude (25.6775.77%;
Po0.01 and 45.072.88%). TIIA at a concentration of 100 mM
displayed a similar effect compared to TIIA 50 mM (data not
shown). The diterpenoid at a concentration of 50 mM was also
investigated for its effect on irreversible aggregation (Fig. 3). TIIA
only partially inhibited the platelet aggregation induced by ADP
(10 mM) or by collagen (10 mg/mL) in terms of AUC (16.1075.6%
and 9.2570.75% for ADP and collagen respectively; Po0.05) and
amplitude (9.6170.92% and 5.5271.50% for ADP and collagen
respectively; Po0.05) (Figs. 3A and 3B).
The lowest concentration of TIIA (0.5 and 5 mM) did not affect
platelet aggregation, whereas TIIA at a concentration of 100 mM
displayed a similar effect compared to TIIA 50 mM (data not shown).
3.2. Effect of TIIA on platelet tubulin acetylation and p-erk signaling
Figs. 4A and 5A show a representative Western blot and
related cumulative densitometric analysis (Fig. 4B and Fig. 5B)
Fig. 1. Typical records of platelet aggregation. Figures present aggregation curves following addition of 0.5 (A), 5 (B) and 50 μM (C) of TIIA or 50 μM (D) of ASA compared to
TIIA/ASA-vehicle, after addition of ADP 3 μM.
Fig. 2. Concentration dependent effect of TIIA on ADP-induced platelet aggrega-
tion. Rat PRP were incubated with TIIA (0.5–50 μM) or ASA (50 μM) for 1 min, and
then exposed to ADP (3 μM) to induce platelet aggregation. Percent (%) inhibition of
aggregation was expressed in terms of AUC (A) or amplitude (B) calculated as the
difference between the maximum value of aggregation in presence of ADP plus
vehicle and the value obtained in the presence of ADP plus TIIA or ASA. Data are
expressed as mean7SEM. nPo0.05 vs vehicle,nnPo0.01 vs vehicle, nnnPo0.001 vs
vehicle (one way ANOVA; n¼7–10).
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of rat PRP lysates non-stimulated (ctrl) or collected 1, 3 and 5 min
after the stimulation with ADP (3 mM) or ADP plus TIIA (50 mM)
and successively blotted for acetylated tubulin and p-Erk-2
antibodies.
Fig. 4B shows that platelets of the ctrl group had elevated levels
of acetylated tubulin at all time points. These levels were sig-
niﬁcantly reduced in the presence of ADP and were reverted 1 and
3 min after incubation with TIIA.
Fig. 5B shows that the platelet of the ctrl group did not shown
any increase in intracellular signaling of p-Erk-2 for all time points.
Stimulation with ADP induced a time-dependent increase in Erk-2
phosphorylation that peaked between 3 and 5 min. Pre-incubation
with TIIA signiﬁcantly reduced p-Erk signaling at 3 min.
3.3. Effect of TIIA on in vivo bleeding time
As shown in Fig. 6, the pretreatment of mice with TIIA (10 mg/
kg, i.p.) signiﬁcantly increased mice bleeding time (2.0670.29 min;
Po 0.01) compared to the control group (1.2970.07 min). Similar
results were observed after ASA administration (2.2870.34 vs
0.7570.20 min; Po 0.01).
Fig. 3. Effect of TIIA on ADP (10 μM) and collagen (10 μg/mL)-induced platelet aggregation. Rat PRP were incubated with TIIA (50 μM) for 1 min, and then exposed to the pro-
aggregatory stimuli (ADP or collagen). Percent (%) inhibition of aggregation expressed in terms of AUC (A) and amplitude (B) was calculated as the difference between the
maximum value of aggregation in presence of the stimuli plus vehicles and the value obtained in the presence of TIIA. Data are expressed as mean7SEM. nPo0.05 vs vehicle
(Student's t-test; n¼7).
Fig. 4. Representative Western blotting (A) and related cumulative densytometric analyses (B) of acetylated tubulin (ac-tubulin) and tubulin in rat PRP stimulated with ADP
(3 μM) plus TIIA-vehicle or with ADP (3 μM) plus TIIA (50 μM) at indicated time point. Data were expressed as mean7SEM. O.D. (optical density) normalized against
tubulin.nPo0.05 vs ctrl,nnPo0.01 vs ctrl, ♯Po0.05 vs ADP plus TIIA-vehicle, ♯♯Po0.01 vs ADP plus TIIA-vehicle (one way ANOVA followed by Student's t-test, n¼3).
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However the fold increase of mice bleeding time was higher in
ASA (204%, ASA vs vehicle group) compared to TIIA treated mice
(58%, TIIA vs vehicle group).
4. Discussion
Danshen has long been used in the treatment of cardiovascular-
related disorders. Interest in its versatile protective effects in
cardiovascular and neurodegenerative diseases has been growing
over the last decade (Zeng et al., 2012; Wu and Wang, 2012; Xu
and Liu, 2013; Sheng et al., 2014).
Tanshinones, the major lipophilic components extracted from
Danshen, are known to exhibit potent cardiovascular effects (Gao
et al., 2012). In the early observations Li et al. (1984) demonstrated
that tanshinone IIA sulfonate affected thrombus formation and
blood coagulation in rats and mice and successively Lee et al.
(1987) reported that isotanshinone IIB inhibits ADP- and collagen-
induced platelet aggregation in vitro. A most recent paper pub-
lished by Liu et al. (2011) also demonstrated the effect of TIIA on
platelet aggregation in healthy newborn piglets. Other bioactives
components extracted from Danshen, as such as oleoylneocrypto-
tanshinone II and oleoyl danshenxinkun A were also reported to
inhibit platelet aggregation induced by arachidonic acid in rabbits
(Lin et al., 2001).
Tanshinone IIA has been introduced as the most abundant and
representative principle of all tanshinones present in Danshen
(Gao et al., 2012). On this basis, in this study we tested the
hypothesis that TIIA inhibited the platelet aggregation induced
by collagen and ADP via the modulation of tubulin acetylation and
inhibition of Erk-2 phosphorilation. The effect of the diterpenoid
was also studied in vivo on bleeding time in mice.
Our results show that TIIA in vitro inhibits, in a concentration
dependent manner, rat platelet aggregation induced by ADP 3 mM
(primary aggregation). The observed effect was similar to ASA in
terms of percentage of inhibition of platelet aggregation. However,
TIIA displayed a less extent of activity on irreversible stimuli
induced by ADP 10 mM or by collagen 10 mg/mL.
Platelet activation can be part of the normal hemostatic
response to injury or a pathological reaction to disease. In the
complex scenario of vascular injury, platelets initially are activated
by collagen from the vessel wall. This led activated platelets to
release mainly ADP and successively other mediators which
Fig. 5. Representative Western blotting (A) and related cumulative densytometric analyses (B) of p-Erk2 and total Erk-2 in rat PRP stimulated with ADP (3 μM) plus
TIIA-vehicle or with ADP (3 μM) plus TIIA (50 μM) at indicated time point. Data were expressed as mean7SEM. O.D. (optical density) normalized against Erk-2.nnPo0.01 vs
ctrl, ♯Po0.05 vs ADP plus TIIA (one way ANOVA followed by Student's t-test, n¼3).
Fig. 6. Effect of TIIA on mouse tail bleeding time. TIIA (10 mg/kg) or ASA (10 mg/kg)
were administered i.p. to CD1 mice 1 h before the experiments. Data were
expressed as the mean7S.E.M.nnPo0.01 vs respective vehicles. (Student's t-test,
n¼8–10).
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reinforce the platelet activation response and plug (Kunapuli,
1998; Pitchford, 2007). Platelet plug formation can proceed
beyond thrombus growth. This might occur in case an excessive
local presence of molecules that exert an autocrine and paracrine
aggregatory effects, such as nitride oxide (NO) and matrix metal-
loproteinase (MMP). NO, released under basal conditions and in
response to platelet receptor agonists such as ADP, interacts
directly with circulating platelets and exerts its effects by activat-
ing soluble guanylyl cyclase in vascular smooth muscle, which in
turn leads to the formation of cyclic guanosine monophosphate
(cGMP) and to relaxation. On the other hand, independent of their
matrix degrading activity, MMPs also regulate some cell functions
relevant to atherothrombosis and thrombus stability, such as
platelet activation, neutrophil activation, and vascular reactivity
(Tschudi and Lüscher, 1996; Santos-Martínez et al., 2008).
In platelets, tubulin acetylation has an important role in the
control of microtubule structure and microtubule-based cellular
functions. However, upon activation, platelets undergo a dramatic
change in shape as a result of microtubules reorganizations
suggesting that their deacetylation is associated with cell activa-
tion (Aslan et al., 2013; Sadoul et al., 2012). To conﬁrm the effects
of TIIA on platelets, we next measured the effect of TIIA on tubulin
acetylation signaling in rat pre-activated platelets. Intriguely and
consistently with results obtained in the aggregation assay, plate-
lets treated with TIIA (50 mM) displayed faster kinetics of tubulin
acetylation compared to platelets stimulated with ADP alone, up to
a period of 3 min, indicating a speciﬁc effect of TIIA on the kinetics
of platelet activation.
In platelets, MAPKs mainly contributed to platelet activation
and aggregation induced by various stimuli. Moreover, recent
works show that phosphorylation of predominantly Erk-2, but
not Erk-1, occurs in platelets stimulated with P2Y receptor ago-
nists, such as ADP (Adam et al., 2008; Garcia et al., 2007). To gain
insight into the mechanism of TIIA, we investigated the effect of
the tanshinone on MAPKs signaling on rat platelets. Experiments
performed on PRP lysates collected at different time-point after
the addition of the stimuli showed that TIIA (50 mM) selectively
inhibited at 3 min MAPK signaling pathways such as Erk-2
phosphorylation compared to the ADP-stimulated platelet. These
results demonstrate that the effects of TIIA on tubulin acetylation
could be related to a concomitantly inhibition of Erk-2 signaling.
Recent evidences demonstrated that Danshen may have effects
on blood clotting and that potentiates the effects of the common
anticoagulation drugs such as warfarin (Chan, 2001), suggesting an
implication of tanshinones on blood stasis. As shown in our in vivo
experiments, TIIA (10 mg/kg) signiﬁcantly prolonged the bleeding
time in mice compared with the control group (Po0.01), con-
ﬁrming the effect of the diterpenoid on in vitro platelet aggrega-
tion. In vitro, we observed that TIIA inhibited primary aggregation
through inhibition of ADP and collagen-induced platelet aggrega-
tion. This effect is also reﬂected in vivo in an increased mice
bleeding time. Probably, the in vivo effect of TIIA is due to a
reduced platelet adhesion to the vascular wall and the following
reduced response to endogenous ADP.
5. Conclusion
In the present study, we have examined the effect of TIIA on
platelet aggregation induced by different stimuli and we have
investigated the mechanism underlying its action. Our paper
clariﬁes the intracellular signaling pathway involved in this
process and also gives preliminary evidences for its anticoagulant
activity. For these reasons, this compound could be a promising
agent to improve blood viscosity and microcirculation and to
prevent CVD.
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